TIDMAPH

RNS Number : 4169O

Alliance Pharma PLC

02 October 2023

 
 For immediate release   02 Oct 2023

ALLIANCE PHARMA PLC

("Alliance" or the "Company")

Total Voting Rights

Alliance Pharma plc (AIM: APH), the international healthcare group, makes the following notification in accordance with the UK Financial Conduct Authority's Disclosure and Transparency Rule 5.6.1.

As at 30 September 2023 the Company's issued share capital consists of 540,164,462 Ordinary Shares of 1p each.

The total number of voting rights in the Company is 540,164,462 and this figure may be used by shareholders as the denominator for the calculations by which they should determine if they are required to notify their interest in, or change to their interest in, the Company under the FCA's Disclosure Guidance and Transparency Rules.

For further information:

 
 Alliance Pharma plc                              + 44 (0)1249 466966 
 Head of Investor Relations: Cora McCallum        + 44 (0)1249 705168 
 ir@allianceph.com 
 
                                                      + 44 (0)20 7466 
 Buchanan                                                        5000 
 Mark Court / Sophie Wills / Hannah Ratcliff 
 alliancepharma@buchanan.uk.com 
 
 Numis Securities Limited (Nominated Adviser          + 44 (0)20 7260 
  and Joint Broker )                                             1000 
 Nominated Adviser: Freddie Barnfield / Duncan 
  Monteith / Sher Shah 
 
                                                      + 44 (0)20 7597 
 Investec Bank plc (Joint Broker)                                5970 
 Patrick Robb / Maria Gomez de Olea

About Alliance

Alliance Pharma plc (AIM: APH) is a growing consumer healthcare company . Our purpose is to empower people to make a positive difference to their health and wellbeing by making our trusted and proven brands available around the world.

We deliver organic growth through investing in our priority brands and channels, in related innovation, and through selective geographic expansion to increase the reach of our brands. Periodically, we may look to enhance our organic growth through selective, complementary acquisitions .

Headquartered in the UK, the Group employs around 285 people based in locations across Europe, North America, and the Asia Pacific region. By outsourcing our manufacturing and logistics we remain asset-light and focused on maximising the value we can bring, both to our stakeholders and to our brands. For more information on Alliance, please visit our website : www.alliancepharmaceuticals.com

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

TVRUPGCGUUPWGCP

(END) Dow Jones Newswires

October 02, 2023 10:14 ET (14:14 GMT)

Alliance Pharma (LSE:APH)
Historical Stock Chart
From Mar 2024 to Apr 2024 Click Here for more Alliance Pharma Charts.
Alliance Pharma (LSE:APH)
Historical Stock Chart
From Apr 2023 to Apr 2024 Click Here for more Alliance Pharma Charts.